Novartis "buy"

16.01.07 - Dresdner Kleinwort Wasser.

LONDON, January 15 (newratings.com) - Analysts at Dresdner Kleinwort maintain their "buy" rating on Novartis (NOVN). The target price is set to CHF85.

In a research note published yesterday, the analysts mention that the company is expected to post its FY06 sales and EPS growth in-line with the consensus. The analysts expect Novartis? results for the year to be driven primarily by drug launches. The company is poised to benefit going forward from the upcoming launch of Tekturna, Galvus and Exforge, which is expected to occur on schedule in the current year, Dresdner Kleinwort adds.